Literature DB >> 15254417

Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells.

Mikhail V Blagosklonny1, Zbigniew Darzynkiewicz, H Dorota Halicka, Piotr Pozarowski, Zoya N Demidenko, James J Barry, Kalpana R Kamath, Robert A Herrmann.   

Abstract

Paclitaxel (PTX), a microtubule-active drug, causes mitotic arrest leading to apoptosis in certain tumor cell lines. Here we investigated the effects of PTX on human arterial smooth muscle cell (SMC) cells. In SMC, PTX caused both (a) primary arrest in G(1) and (b) post-mitotic arrest in G(1). Post-mitotic cells were multinucleated (MN) with either 2C (near-diploid) or 4C (tetraploid) DNA content. At PTX concentrations above 12 ng/ml, MN cells had 4C DNA content consistent with the lack of cytokinesis during abortive mitosis. Treatment with 6-12 ng/ml PTX yielded MN cells with 2C DNA content. Finally, 1-6 ng/ml of PTX, the lowest concentrations that affected cell proliferation, caused G(1) arrest without multinucleation. It is important that PTX did not cause apoptosis in SMC. The absence of apoptosis could be explained by mitotic exit and G(1) arrest as well as by low constitutive levels of caspase expression and by p53 and p21 induction. Thus, following transient mitotic arrest, SMC exit mitosis to form MN cells. These post-mitotic cells were subsequently arrested in G(1) but maintained normal elongated morphology and were viable for at least 21 days. We conclude that in SMC PTX causes post-mitotic cell cycle arrest rather than cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254417

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  14 in total

1.  Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.

Authors:  R M Hartley; J Peng; G A Fest; S Dakshanamurthy; D E Frantz; M L Brown; S L Mooberry
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

2.  Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.

Authors:  Lauren Lee; Lyda M Robb; Megan Lee; Ryan Davis; Hilary Mackay; Sameer Chavda; Balaji Babu; Erin L O'Brien; April L Risinger; Susan L Mooberry; Moses Lee
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

Review 3.  Taccalonolides: Novel microtubule stabilizers with clinical potential.

Authors:  April L Risinger; Susan L Mooberry
Journal:  Cancer Lett       Date:  2009-10-31       Impact factor: 8.679

Review 4.  Intimal Hyperplasia and Arteriovenous Fistula Failure: Looking Beyond Size Differences.

Authors:  Roberto I Vazquez-Padron; Juan C Duque; Marwan Tabbara; Loay H Salman; Laisel Martinez
Journal:  Kidney360       Date:  2021-08

5.  Function-oriented synthesis: biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy.

Authors:  Susan L Mooberry; Michael K Hilinski; Erin A Clark; Paul A Wender
Journal:  Mol Pharm       Date:  2008-07-29       Impact factor: 4.939

6.  Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1.

Authors:  Fengfeng L Xu; Youssef Rbaibi; Kirill Kiselyov; John S Lazo; Peter Wipf; William S Saunders
Journal:  BMC Chem Biol       Date:  2010-02-11

7.  Septin cooperation with tubulin polyglutamylation contributes to cancer cell adaptation to taxanes.

Authors:  Laurence Froidevaux-Klipfel; Benjamin Targa; Isabelle Cantaloube; Hayat Ahmed-Zaïd; Christian Poüs; Anita Baillet
Journal:  Oncotarget       Date:  2015-11-03

8.  Simultaneous Targeting Tumor Cells and Cancer-Associated Fibroblasts with a Paclitaxel-Hyaluronan Bioconjugate: In Vitro Evaluation in Non-Melanoma Skin Cancer.

Authors:  Barbara Bellei; Silvia Caputo; Emilia Migliano; Gianluca Lopez; Valeria Marcaccini; Carlo Cota; Mauro Picardo
Journal:  Biomedicines       Date:  2021-05-24

9.  New stent design for use in small coronary arteries during percutaneous coronary intervention.

Authors:  Juan F Granada; Barbara A Huibregtse; Keith D Dawkins
Journal:  Med Devices (Auckl)       Date:  2010-10-19

10.  Panaxquin quefolium diolsaponins dose-dependently inhibits the proliferation of vascular smooth muscle cells by downregulating proto-oncogene expression.

Authors:  Zhihao Wang; Yingkai Wang; Xuezhong Zhao
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.